Panacea Biotec has received a ₹315 crore order from UNICEF for the supply of bivalent oral polio vaccine. The deal, part of a long-term agreement, covers deliveries from April 2026 to March 2030 in 10 and 20-vial formats.
Source: Panacea Biotec Press Release (NSE Exchange Fillings) | Published on Oct 06, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Panacea Biotec (NSE Exchange Filings), the company announced that it has received a Letter of Award (LoA) from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of bivalent oral polio vaccine (bOPV). The deal is worth approximately ₹315 crores (USD 35.65 million) and will cover deliveries from April 1, 2026, to March 31, 2030.
The arrangement is under a long-term global supply agreement and the vaccines will be supplied in both 10-vial and 20-vial presentations to meet UNICEF requirements during the contract period. The supplies to UNICEF will cover between Q2 CY2026 to CY2027, and UNICEF announced the award in conjunction with its published award information, which details the full award including name of supplier, type of vaccine, value of award and pricing details on its official website.
Also read: Tata Steel receives ₹2,410 cr demand from Jajpur mines office
Panacea Biotec to supply bOPV worth ₹315 crore to UNICEF.
Contract runs from April 2026 to March 2030.
Vaccines to be supplied in 10-vial and 20-vial formats.
Agreement covers Q2 CY2026 to CY2027 deliveries.
Also read: US FDA Flags Lupin’s Pithampur Unit-2 as Official Action Indicated
The contract’s international scope highlights Panacea Biotec’s ongoing role in supplying critical vaccines to global immunisation programmes. The order will be executed under a long-term agreement (LTA) structure, allowing UNICEF to place orders based on its requirements over the contract duration.
The supply details include the following:
Parameter | Details |
Total contract value | ₹315 crore (USD 35.65 million) |
Duration | 1 April 2026 – 31 March 2030 |
Product | Bivalent Oral Polio Vaccine (bOPV) |
Vial sizes | 10 and 20 vials |
Supply period | Q2 CY2026 – CY2027 |
This advancement demonstrates ongoing demand for bOPV in international health programs and validates Panacea Biotec's position as a key supplier of vaccines. The agreement enables the organisation to expand its portfolio and provides a reliable source of revenue during the execution period.
The order also confirms that there are no related-party connections between the promoters or group companies of Panacea Biotec and UNICEF, indicating that the agreement is strictly commercial. The company has indicated that it will provide vaccines consistent with UNICEF's request for the length of the order.
Markets reacted favorably to the announcement. Panacea Biotec share price was at ₹415.00 on the BSE as of 3 October 2025 at 15:30 PM IST, an increase of ₹12.85 or 3.20% on the day of the announcement.
The movement of the share price represents market confidence in the company's capacity to secure substantial large multinational orders and maintain its business in vaccines. Revenue implications will take years to be realised, but contracts like these provide visibility to steady revenues, and underscore the positioning of the company in the global immunisation ecosystem.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading